Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir

Journal of Hepatology

Volumn 63, Issue 2, 2015, Pages 337-345

  Younossi, Zobair M ^a,b   Stepanova, Maria ^b,c   Afdhal, Nezam ^d   Kowdley, Kris V ^e   Zeuzem, Stefan ^f   Henry, Linda ^c   Hunt, Sharon L ^b   Marcellin, Patrick ^g  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g BEAUJON HOSPITAL   (France)

Author keywords

Direct acting antivirals; Fatigue; Fibrosis; HCV; Health related quality of life; Patient reported outcomes; Ribavirin; Work productivity

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE QUESTIONNAIRE HCV; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; TREATMENT INDICATION; VIRAL CLEARANCE; WORK PRODUCTIVITY AND ACTIVITY INDEX SPECIFC HEALTH PROBLEM; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUALITY OF LIFE; SOFOSBUVIR; SURVEYS AND QUESTIONNAIRES;

EID: 84936849320     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.014     Document Type: Article

References (28)

1. Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Rep 2010;12:1-6.
2. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013:1859-1861.
3. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014;20:9633-9652.
4. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014;39:518-531.
5. Verna EC. Hepatitis viruses and liver transplantation: evolving trends in antiviral management. Clin Liver Dis 2014;18:575-601.
6. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 2005;19:S53-S63.
7. Morais-de-Jesus M, Daltro-Oliveira R, Pettersen KM, Dantas-Duarte A, Amaral LD, Cavalcanti-Ribeiro P, et al. Hepatitis C virus infection as a traumatic experience. PLoS One 2014;9:e110529.
8. Quarantini LC, Miranda-Scippa A, Rocha M, Bressan RA. Neuropsychological function in patients with chronic hepatitis C. Liver Int 2008;28:893-894.
9. Batista-Neves SC, Quarantini LC, de Almeida AG, Bressan RA, Lacerda AL, de- Oliveira IR, et al. High frequency of unrecognized mental disorders in HCVinfected patients. Gen Hosp Psychiatry 2008;30:80-82.
10. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al. Effects of antiviral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol 2012;56:549-556.
11. Forton DM. Hepatitis C treatment-clearing the mind. J Hepatol 2012;56:513-514.
12. Alsop D, Younossi Z, Stepanova M, Afdhal N. Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 naïve patients treated with ledipasvir and sofosbuvir. Hepatol 2014;60(Supplement S1):221A.
13. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010;8:1017-1029.
14. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800.
15. Martin LM, Younossi ZM. Health-related quality of life (HRQL) in chronic liver disease. Dig Liver Dis 2005;37:819-820.
16. DiBonaventura Md, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011;14:253-261.
17. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011;17:657-664.
18. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010;52:436-442.
19. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007;52:2531-2539.
20. McHutchison JG, Ware Jr JE, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-147.
21. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007;45:806-816.
22. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, et al. Changes in quality of life and sexual health are associated with lowdose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010;31:719-734.
23. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007;46:420-431.
24. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011;31:18-22.
25. Ware Jr JE, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30:550-555.
26. Ghany MG, Strader DB, Thomas DL, Seeff LBAmerican Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
27. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 2013;20:550-555.
28. Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014;59: 2161-2169.